To the best of our knowledge, this is the first study to reveal the central role of ZEB1 in conferring resistance to gefitinib by not only inducing EMT but also by maintaining the CSC phenotype in NSCLC by regulating expression of miR‐200c and BMI1, along with activating EGFR mutations. Here, ZEB1 is linked to non-small cell lung carcinoma.